Growth Strategy (The Second Medium-Term Management Plan)

The environment surrounding the pharmaceutical industry is rapidly changing, and in new drug development and the healthcare field, there are various growth opportunities such as the increasing activity of open innovation, the creation of new value through collaboration with different industries, and the rising importance of self-medication. We aim to become a globally competitive company that can respond to any situations flexibly and swiftly by implementing four growth strategies: Maximization of Product Value – From a Patient-Centered Perspective –, Reinforcement of Pipelines, Acceleration of Global Business Advancement, and Expansion of Business Domains. Furthermore, we are striving to strengthen our management infrastructures to support these growth strategies.

Strengthen the Management Infrastructures and Implement the Four Growth Strategies

Growth Strategy: Maximization of Product Value - From a Patient-Centered Perspective -
We work together with healthcare professionals to realize the well-being of patients and their families (a state in which physical, mental, and social well-being and overall life satisfaction are fulfilled), and as a result, aiming to achieve the rapid penetration of new drugs. To that end, we are committed to fast and effective development, competitive marketing, and precise provision and collection of information. In marketing and information activities, we are developing specialty talents that tackle medical challenges together with healthcare professionals from the patient’s perspective, while leveraging digital tools to deliver and gather information effectively and efficiently to maximize each product’s potential.
For “OPDIVO,” one of our key oncology products, we will continue working with our partner, Bristol Myers Squibb, to deliver long-term survival to cancer patients and will keep striving to maximize the product’s value.
For “ONGENTYS,” one of our key primary-care products, we will work to expand recognition of its benefits in the early stages of wearing-off in patients with Parkinson’s disease and to encourage timely identification of wearing-off, aiming to position it as the first-choice adjunct therapy for Parkinson’s disease and pursue further growth.

Growth Strategy: Reinforcement of Pipelines
We are aiming to become a “global specialty pharma” company capable of meeting unmet medical needs. In drug discovery research, under our policy of “creating innovative, breakthrough new medicines,” we have identified oncology, immunology & inflammation and neurology as priority areas with high levels of medical needs. We are actively promoting open innovation and, by incorporating Deciphera’s unique approach as well, are working to strengthen our drug discovery capabilities. We also actively leverage nonclinical data using human samples and clinical trial data to validate drug targets and enhance translational research, thereby improving the probability of success in R&D.
In clinical development, we are currently conducting nearly 100 clinical trials as Ono Group. With a focus on strengthening the quality of our clinical-stage pipeline, we are working to quickly reach a state in which we are running many confirmatory clinical studies. In addition, we are also placing emphasis on strengthening our global development structure; by leveraging Deciphera’s development platform, we will accelerate global development and aim to launch innovative new medicines globally as quickly as possible.
Furthermore, we will proactively advance licensing activities for drug candidates under development by pharmaceutical companies and biotech ventures in Japan and overseas, bringing in attractive candidates for diseases with high medical needs or strong strategic fit, and further strengthening our pipeline.

Growth Strategy: Acceleration of Global Business Advancement
To deliver innovative medicines swiftly to patients worldwide, we are working to expand and accelerate our global business. To that end, we acquired Deciphera, strengthening our development pipeline and R&D capabilities while also gaining a commercial platform in the U.S. and Europe. We have also positioned Deciphera as the hub for our U.S. and European business and reorganized and consolidated the functions we previously maintained in the U.S. and the U.K. This will enable us, as one group, to further accelerate our global business.
As specific initiatives, we will maximize product value by pursuing additional indications and expanding the sales territories for QINLOCK and ROMVIMZA, while also advancing efforts toward the U.S. launch of ONO-4059 (VELEXBRU Tablets). Going forward, we will continue working to deliver new value to more patients around the world and to achieve sustainable growth for our group.

Growth Strategy: Expansion of Business Domains
We are committed to expanding our business domains to capture the needs of expanding healthcare sector and continue to deliver new value. At Ono Pharma Healthcare Co., Ltd., we are developing Foods with Functional Claims that make maximum use of the assets we have built through R&D in prescription pharmaceuticals, and we sell our first product, the sleep supplement “REMWELL,” directly to consumers. For “SAEFULL,” a cognitive function supplement newly accepted for notification as a Food with Functional Claims, we are advancing preparations for launch. As a pioneer in lipid research, we will work through our lipid supplement business to address an even broader range of health challenges going forward.
In addition, to leverage digital technology, engage with customers’ unresolved issues, and take on the challenge of creating new value, michiteku, Co., Ltd. provides “michiteku Web,” a tool that supports emotional care immediately after cancer diagnosis (colorectal, gastric, lung, breast, cervical, and endometrial cancers) and helps patients to improve health literacy to better understand what their physicians tell them, as well as “michiteku YOHA,” an application for managing hospital visit days to support balancing between daily life and treatment.
Alongside these initiatives, we aim to create and expand new businesses through investment in healthcare ventures by Ono Digital Health Investment, GK.

Management Infrastructures to Support Growth Strategies
To support our four growth strategies and achieve transformative growth, we have established and are advancing initiatives in “Corporate Transformation through Digital & IT,” “Ensuring Quality and Safety,” “Strengthening Supply Reliability,” “Promotion of Strategic Growth Investments,” “Corporate Branding,” “Protection of Corporate Value,” and “Expansion of Human Capital.” Through these initiatives, we will work to strengthen our management infrastructures and further propel our growth strategies.